Panel discussion 'Right to Try'
13:30 - 14:00 | Rotterdam Hall
Societal changes and digital innovation have led to growing patient empowerment in healthcare. In the U.S. ‘Right-to-try’ laws have even been created to give terminally ill patients access to novel drugs that are not yet approved by the FDA, but are likely to save their lives.
What are the pros and cons of giving patients early access to experimental drugs? Should patients have extra options beyond what is currently available via compassionate use?
During this panel session we will discuss this topic with stakeholders from different perspectives.
Janssen & Vereniging Innovatieve Geneesmiddelen
Maurits van Selms
ALS patient & ACTA
Ton de Boer
Medicine Evaluation Board
Ingmar de Gooijer
Are you a CEO or an investor and interested to network with high level delegates during our special VIP CEO-Investor evening programme and dinner? Book your tickets now!
The (provisional) programme of Innovation for Health 2019 is now online! Are you as excited as we are about the themes, sessions and speakers of this years' edition?
Check this years' programme
An exciting part of the programme is the yearly start-up pitch contest. Ten start-up companies will get the opportunity to pitch their company and healthcare innovation to key players and decision makers in Health & Life sciences sector on 14 February at Innovation for Health and Global Investor Forum! Find out who is selected to compete in the yearly start-up pitch contest!
Check it here!
© 2018 Innovation for Health